The US FDA warns users of smartphone-linked diabetes devices like CGMs and insulin pumps of potential health risks due to missed critical alerts. Issu ...
H.C. Wainwright reiterated its Buy rating and $80.00 price target for Corcept Therapeutics (NASDAQ:CORT), highlighting the company's consistent growth in Korlym sales over the past eight quarters ...